← All Biote CORP filings

Biote CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BTMD
Biote CORP
10-K: Biote Corp. Faces Revenue Decline, Control Weakness Amid Recall
Biote Corp. reported a 2.5% revenue decrease and an 8.1% Adjusted EBITDA decline for 2025, alongside un-remediated internal control weaknesses and a product recall, despite a significant increase in net income driven by non-operating gains.
NASDAQ
BTMD
Biote CORP
10-K: Biote Corp. Reports Fiscal Year 2024 Results, Navigates Leadership Transition and Strategic Acquisitions
Biote Corp. announces its FY2024 financial results, highlighting revenue growth, a leadership transition, and strategic acquisitions aimed at strengthening its position in the hormone optimization market.
NASDAQ
BTMD
Biote CORP
10-K: Biote Corp. Outlines Securities and Governance in Annual 10-K Filing
Biote Corp.'s annual 10-K filing details the company's authorized and outstanding stock, warrant terms, and various corporate governance provisions.